支气管哮喘(以下简称哮喘)是由多种细胞(嗜酸性粒细胞、T细胞、肥大细胞、中性粒细胞等)和细胞组分参与的气道慢性炎症性疾病,以气道慢性炎症、气道高反应性和气道重塑为发病特征~([1])。其发生机制复杂,目前尚未完全阐明,近年来免疫学机制以及以免疫学为靶点的治疗策略已成为当下研究的热点~([2-3])。灭活草分支杆菌作为一种多功能强的免疫刺激剂,具有免疫调节作用,在哮喘的治疗过程中得到极大的关注~([4-5])。本文就哮喘的发病机制以及草分枝杆菌在哮喘治疗中的最新研究进展予 Bronchial asthma (hereinafter referred to as asthma) is a chronic inflammatory disease of the airways involving a variety of cells (eosinophils, T cells, mast cells, neutrophils, etc.) and cellular components, with chronic airway inflammation, Pathological hyperresponsiveness and airway remodeling as the incidence of ~ ([1]). The mechanism of its occurrence is complex and not yet fully elucidated. In recent years, immunological mechanisms and immunotherapy as the target of the treatment strategy has become the focus of current research (2-3). Inactivated Mycobacterium tuberculosis, as a multifunctional and powerful immunostimulant with immunomodulatory effects, has received great attention in the treatment of asthma (4-5). This article on the pathogenesis of asthma and Mycobacterium phlei in the treatment of asthma in the latest research progress to